Neurophysiology

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

Retrieved on: 
Monday, November 28, 2022
Marketing, Remyelination, LS, Cognition, Neuroprotection, Brain, Randomness, Biomarker, CNM, Research, Neurodegeneration, SAP, Preferred walking speed, Multiple sclerosis, Treatment, SALT, MS, Patient, COVID, Mitt, FDA, COVID-19, ITT, R, Drug Quality and Security Act, Annual report, MRI, Efficacy, DMTS, Safety, Neurophysiology, PIRA, Gold, Committee, MD, Multiple sclerosis functional composite, Catalytic Communities, Congress, MBBS, HIV disease progression rates, Medical imaging, Pharmaceutical industry, Medicine, Risk management

These data provided consistent supportive evidence from neurophysiology, retinal imaging, and novel MRI markers for the potential neuroprotective and remyelinating effects of CNM-Au8 treatment.

Key Points: 
  • These data provided consistent supportive evidence from neurophysiology, retinal imaging, and novel MRI markers for the potential neuroprotective and remyelinating effects of CNM-Au8 treatment.
  • Placebo treated patients generally worsened across clinical and paraclinical measures during the 48-week period.
  • Robert Glanzman, MD FAAN, Chief Medical Officer at Clene, added, CNM-Au8s demonstration of neurological improvement in stable MS patients is very encouraging.
  • The currently available MS disease-modifying therapies are very successful at limiting relapses but do not address disease progression independent of relapse activity.

The Global Medical Electrodes Market size is expected to reach $2 Billion by 2028, rising at a market growth of 3.8% CAGR during the forecast period

Retrieved on: 
Monday, November 28, 2022
Neurophysiology, Neurological disorder, Heart, ECG, Skin, Scalp, TENS, BCIS, Electrode, Diagnosis, EMG, Electroencephalography, Degenerative disease, Electromyography, Prevalence, Lead, Brain, Medtronic, Patient, IOM, Electrocardiography, Aarhus University, Electrosurgery, Electricity, Death, EEG, Metal, CVD, Becton, Dickinson and Company headquarters, Sleep, Carbon, Research, Muscle, The Cooper Companies, 3M, Needle, Medicine, Infarction, Stroke, Cardiology, Medical device, Pharmaceutical industry

View original content:https://www.prnewswire.com/news-releases/the-global-medical-electrodes-m...

Key Points: 
  • NEW YORK, Nov. 28, 2022 /PRNewswire/ -- The Global Medical Electrodes Market size is expected to reach $2 Billion by 2028, rising at a market growth of 3.8% CAGR during the forecast period.
  • In the coming years, the medical electrode market is bound to grow owing to the increased R&D in the field.
  • Based on product type, the medical electrodes market is bifurcated into surface electrodes and needle electrodes.
  • On the basis of application, the medical electrodes market is divided into cardiology, neurophysiology, electrosurgery, interoperative monitoring (IOM), and sleep study.

JSI Names Dr. Sylvia Bartley as Chief of Staff

Retrieved on: 
Tuesday, November 15, 2022
Emory University, AARP, Health, ABFE, Doctor of Philosophy, Goal, Board, JSI, University of East London, Georgia Tech, Heart, St. Barts, Dentistry, Biomedical engineering, Advisory board, Sitara-i-Imtiaz, Student, Medtronic, Organization, Woman, Physician, Partnership, Association, Pollen, Wallace H. Coulter Department of Biomedical Engineering, Neuroscience, Education, Healthcare disparity in Massachusetts, Patient, Female, Black, Biomedicine, Augsburg University, The Wallace, Richie Campbell (singer), Director, Health equity, Islamic World Educational, Scientific and Cultural Organization, List, Women in business, African, Radio, STEM, Solution, Management, Neurophysiology, Pharmacology, Spirituality

WASHINGTON, Nov. 15, 2022 /PRNewswire/ -- JSI has named Dr. Sylvia Bartley as Chief of Staff for JSI, the global public health organization, and its affiliate, World Education, Inc. Dr. Bartley brings to the role a distinguished career in healthcare, engaging employees, boards, and organization partners toward achieving strategic health business, philanthropic, and equity goals. 

Key Points: 
  • "JSI is delighted to welcome Sylvia Bartley who has demonstrated extraordinary talent in influencing change, leading people, and working cross-functionally to achieve goals at a global level.
  • Throughout her many accomplishments, she has been a champion for health equity that is at the heart of our mission," said JSI CEO Margaret Crotty.
  • As Chief of Staff, Dr. Bartley will assume an executive role and business departmental responsibilities, working with leaders across the organizations to maximize their strategic, communications, operational, and partnership strengths and achieve goals of improving the health of individuals and communities around the world.
  • Dr. Bartley earned a Ph.D. in Neurophysiology at the St. Barts and The Royal London School of Medicine and Dentistry.

VoxNeuro Announces Collaboration with the Canadian Armed Forces and Launch of Clinical Study Measuring Impact of Training-Related Sub-Concussive Exposure

Retrieved on: 
Tuesday, September 27, 2022
Defense, Health, Medical Devices, Neurology, Health Technology, Military, General Health, Bureau of Oceans and International Environmental and Scientific Affairs, Safety, Neurophysiology, Brain, FDA, Prevalence, Biomarker, Legislation, CAF, Company, Cognition, Partnership, Patient, Phrase, Prognosis, Canadian Armed Forces, Health Canada, Military personnel, Technology, Veteran, Doctor of Philosophy, Diagnosis, Research, EEG, Decision-making, Multimedia, Medical imaging, Toy

This research will hopefully be an important step forward in improving brain health and increasing the safety of the Canadian Armed Forces and other military personnel.

Key Points: 
  • This research will hopefully be an important step forward in improving brain health and increasing the safety of the Canadian Armed Forces and other military personnel.
  • VoxNeuro and CAF intend for this study to lay the foundation for future collaborative research for years to come.
  • VoxNeuro complements existing clinical workflow to provide clinicians and patients with a more complete picture of brain health, and to inform clinical decision-making.
  • The Company does not undertake to update any forward-looking statements, except as may be required by applicable securities laws.

Does Microdosing Impact Meditation? New Study From Beckley Foundation and Quantified Citizen Investigates

Retrieved on: 
Thursday, September 15, 2022
Maastricht University, Beckley Foundation, Time, Safety, Neurophysiology, Psychology, Growth, Risk, Meditation, University of British Columbia, Research, Motivation, GLOBE, Mindfulness, Awareness, University, Teahouse, Medical device

'Enhancing Mindfulness' was reported as the most widely endorsed motivation for microdosing (Rootman et al., 2021) in the largest microdosing study to date, Microdose.me, which was conducted by Quantified Citizen in collaboration with University of British Columbia and Maastricht University.

Key Points: 
  • 'Enhancing Mindfulness' was reported as the most widely endorsed motivation for microdosing (Rootman et al., 2021) in the largest microdosing study to date, Microdose.me, which was conducted by Quantified Citizen in collaboration with University of British Columbia and Maastricht University.
  • The results of this study will help guide future research and improve understanding of the effects of microdosing.
  • To join, please enroll in the Microdose.me study on the Quantified Citizen app .
  • To fuel further growth and development of new study capabilities, Quantified Citizen is currently in the process of raising its Seed+ round of funding.

New members appointed to the Advisory Committee for persons with disabilities

Retrieved on: 
Tuesday, August 30, 2022
University, CRA, Health policy, Legislation, Social policy, Canada Revenue Agency, Disability, Person, Assistant commissioner, DTC, Caledon Institute of Social Policy, DAC, Disablement Advisory Committee, British Columbia Aboriginal Network on Disability Society, Assessment, Medicine, Government revenue, Neurophysiology, Assistant professor, Health insurance, Management, Industrial design

In order to provide fulsome and representative advice, it is important the DAC's membership reflects Canada's rich and diverse population.

Key Points: 
  • In order to provide fulsome and representative advice, it is important the DAC's membership reflects Canada's rich and diverse population.
  • Starting in September, existing committee members Sharon McCarry and Jonathan Lai will assume the roles of private-sector co-chair and vice-chair respectively.
  • "I am delighted to welcome the new members of the Disability Advisory Committee.
  • To date, the DAC has published two reports containing a range of other recommendations on important and emerging issues facing persons with disabilities and their supports.

Disrupting Data Science in Neuroscience Research and AI

Retrieved on: 
Tuesday, August 23, 2022
Machine learning, PR, University, CEO, Technology, Chief executive officer, ScienceDaily, Medtech, Research, Neuron, Gene, Disruption, Brain, White House, Solution, Computational engineering, Public opinion, Electrophysiology, Apple, Evangelist, KJ, Intelligence, BRAIN, Data analysis, Public relations, Laboratory, Student, Baylor College of Medicine, Google Play, Depression, Data science, Map, Baylor University, E-commerce, History, Neocortex, Doctor of Philosophy, Traumatic brain injury, Interrupt, Communication, Neurophysiology, App store, Industry, Environment, COVID, AI, Adoption, DONE, Medical imaging, Management, Mobile phone, Marketing, Science, Finance, Neuroscience

TAMPA BAY, Fla., Aug. 23, 2022 /PRNewswire-PRWeb/ -- In 2013, then-President Obama launched the brain initiative, which allocated funding to map every neuron in the brain. Understanding how the brain works can revolutionize the lives of many Americans, solving the complex problems of Alzheimer's and Parkinson's disease, depression, and traumatic brain injury (1). However, mapping the brain alone does not reveal how it functions. Different parts of the brain appear similar but function differently, and each person has unique brain anatomy (2).

Key Points: 
  • The need for data analysis has allocated neuroscience graduate students to solving complex computer science problems.
  • Dimitri Yatsenko's background in computer science gave him a unique perspective when his fascination with the human brain led him to neuroscience.
  • They develop data science frameworks, platforms, and services for collaborative research, focusing on neuroscience and AI.
  • While engaged in neuroscience research at Baylor College of Medicine, Dimitri started the DataJoint framework as an open source framework https://datajoint.org .

BioMech, ēlizur Announce Partnership Integrating AI-enabled Motion Analytics into Physical Therapy Solution

Retrieved on: 
Wednesday, June 22, 2022
National Accreditation Board for Hospitals & Healthcare Providers, United, Industry, Biophysics, Rehabilitation, Feedback, Compliance, Artificial intelligence, Neurophysiology, Company, Anatomy, LLC, Therapy, Algorithm, SSS, Health, Quality of life, Biomech, Partnership, Patient, Shoulder, Mathematics, Machine learning, Risk, Medical device, Hospital

RICHMOND, Va., June 22, 2022 /PRNewswire/ -- BioMech Health, a division of BioMech Holdings, LLC, and ēlizur, a leading musculoskeletal solutions provider, announced today a groundbreaking agreement to integrate BioMech Lab™ Into the Shoulder Strengthening and Stabilization System (SSS). The national partnership brings together two industry leading mechanical and digital solutions to create an in-home product capable of quantifying rehabilitative outcomes while increasing patient adherence to and engagement with physician-directed physical therapy protocols.

Key Points: 
  • Integrating BioMech Lab into the SSS shoulder device delivers automated functional motion data collection and analysis to measure therapeutic progress.
  • The national partnership brings together two industry leading mechanical and digital solutions to create an in-home product capable of quantifying rehabilitative outcomes while increasing patient adherence to and engagement with physician-directed physical therapy protocols.
  • "Coupling the SSS advanced mechanical technology and BioMech Lab's cutting-edge motion analytics is the perfect union to deliver enhanced therapeutic decision support for improved patient compliance with prescribed physical therapy protocols.
  • BioMech Lab delivers to clinicians the real-time functional motion metrics needed to rapidly evaluate, design, and monitor physical, surgical, pharmaco, and cognitive therapies.

Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 16, 2022
Royal commission, Lysosomal storage disease, U.S. Securities and Exchange Commission, ID, Disease, R, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Research, UTSW, GMP, Toxicology, European Commission, Nasdaq, Webcast, Patient, Insurance, Quality of life, Neurophysiology, GLP, Clinical trial, COVID-19, GAN, Adult, PNS, FDA, CNS, Research and development, AAV, Giant axonal neuropathy, Female, Forward-looking statement, Central nervous system, Biomarker, Compte rendu, Mirare, Sale, Drug development, University of Texas Southwestern Medical Center, Genetic disorder, Administration, SEC, Rett syndrome, Batten disease, CEO, Annual report, GLOBE, Pharmaceutical industry, Online gambling, DALLAS

DALLAS, May 16, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.“In 2022, we are focused on advancing our key programs in Rett syndrome and GAN. We initiated clinical development of TSHA-102 in Rett syndrome and expect preliminary clinical data from the REVEAL study by year-end,” said RA Session II, President, Founder and CEO of Taysha. “Recently, the European Commission granted orphan drug designation for TSHA-120 for GAN, further highlighting the unmet need for treatment options for these patients and the important potential of TSHA-120. We have completed a commercially representative GMP batch for TSHA-120 with release testing currently underway. Our existing capital resources, along with full access to the term loan facility, should fund operating expenses and capital requirements into the fourth quarter of 2023.”   

Key Points: 
  • TSHA-120 is designed to deliver a functional copy of the GAN gene to the CNS and PNS.
  • TSHA-102 in Rett syndrome: a self-complementary intrathecally delivered AAV9 gene replacement therapy under development for the treatment of Rett syndrome.
  • Taysha management will hold a conference call and webcast today at8:00 am ET/7:00 am CTto review its financial and operating results and to provide a corporate update.
  • Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease.

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022
Disorder, Alzheimer's disease, Brain, MRI, Twitter, Nasdaq, Cognitive deficit, Pharmacokinetics, GLOBE, Development, CNS, Government budget balance, Company, Securities Exchange Act of 1934, Securities Act of 1933, Biomarker, Safety, Cognition, CSF, CGMP, Nitric oxide, Neurophysiology, Pharmacology, CIAS, Administration, CYCN, Maritime Transportation Security Act of 2002, Guanylate cyclase, ADV, Mitochondrial encephalomyopathy, Ageing, EEG, LinkedIn, NO, Physiology, SEC, Neuropharmacology, SGC, Research, Pathology, State Administrative Expenses, Therapy, PET, Medical imaging, Pharmaceutical industry, Schizophrenia, Q2, MELAS

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced today clinical development progress for CY6463, its lead program, and first quarter 2022 financial results.

Key Points: 
  • We have recently closed enrollment on our CY6463 studies in MELAS and CIAS and look forward to obtaining topline clinical data from these exploratory studies in Q2 and Q3 2022, respectively.
  • We have also continued to enroll our CY6463 study in Alzheimers Disease with vascular pathology, while efficiently driving Cyclerions earlier stage research programs forward.
  • The MELAS trial ( NCT04475549 ) is an open-label, single-arm study of oral, once-daily CY6463 in adults aged 18 or older with MELAS.
  • Net Loss: Net loss was approximately $13.0 million for the first quarter of 2022, as compared to $13.4 million for the first quarter of 2021.